| Literature DB >> 29185486 |
Dimitrios Varvarousis1, Theodoros Xanthos2, Giulio Ferino3,4, Antonio Noto5, Nicoletta Iacovidou6, Massimo Mura4, Paola Scano7,8, Athanasios Chalkias1,9, Apostolos Papalois10, Fabio De-Giorgio11, Alfonso Baldi12, Paolo Mura3, Chryssoula Staikou6, Matteo Stocchero13, Gabriele Finco3, Ernesto d'Aloja3, Emanuela Locci14.
Abstract
Cardiac arrest (CA) is not a uniform condition and its pathophysiology strongly depends on its cause. In this work we have used a metabolomics approach to study the dynamic metabolic changes occurring in the plasma samples of a swine model following two different causes of CA, namely asphyxia (ACA) and ventricular fibrillation (VFCA). Plasma samples were collected at baseline and every minute during the experimental phases. In order to identify the metabolomics profiles characterizing the two pathological entities, all samples were analysed by 1H NMR spectroscopy and LC-MS/MS spectrometry.The metabolomics fingerprints of ACA and VFCA significantly differed during the peri-arrest period and the resuscitation phase. Major alterations were observed in plasma concentrations of metabolites related to tricarboxylic acid (TCA) cycle, urea cycle, and anaplerotic replenishing of TCA. ACA animals showed significant metabolic disturbances during the asphyxial and CA phases, while for VFCA animals this phenomenon resulted shifted at the resuscitation phase. Interestingly, starting from the asphyxial phase, the ACA animals were stratified in two groups based on their metabolomics profiles that resulted to be correlated with the clinical outcome. Succinate overproduction was observed in the animals with the worse outcome, suggesting a potential prognostic role for this metabolite.Entities:
Mesh:
Year: 2017 PMID: 29185486 PMCID: PMC5707403 DOI: 10.1038/s41598-017-16857-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Overview of the experimental study design and summary of the clinical/hemodynamic parameters. Clinical/hemodynamic parameters (weight, heart rate, MAP, CPP, CO) and arterial blood gas analyses of animals of the ACA and VFCA group at baseline, ROSC and 4 h post-ROSC, along with the p-values for the intergroup comparison calculated using the Student’s t-test. Data are presented as mean ± SD. Vertical lines in the scheme indicate blood draws. ACA = asphyxial cardiac arrest group; VFCA = ventricular fibrillation cardiac arrest group; ROSC = return of spontaneous circulation; MAP = mean arterial pressure; CPP = coronary perfusion pressure; CO = cardiac output; SD = standard deviation; bpm = beats per minute; pO2 = arterial oxygen tension; pCO2 = arterial carbon dioxide tension.
Figure 2Overview of LC-MS/MS quantification of key metabolite changes in plasma samples of animals undergoing asphyxial and dysrhythmic CA. Results, expressed in µmol/L, are graphed as box plots, indicating median values and upper and lower quartile distributions, at baseline, CA (last minute), CPR (last minute), ROSC and post-ROSC (1, 2, 3, 4, 24 h). (a) TCA cycle, urea cycle, lipid metabolism intermediates. (b) Anaplerotic replenishing of TCA cycle. Asterisks indicate statistical significance regarding the within group comparison of each phase with the previous one calculated by paired Wilcoxon t-test (*p-value ≤ 0.05, **p-value ≤ 0.01, ***p-value ≤ 0.001).
Figure 3Comparative analysis of plasma samples during CA. Score scatter plots of the (a) PCA and (b) ptPLS2-DA models of ACA and VFCA plasma samples during the five minutes of CA (one samples per minute). No-damaged ACA samples are represented by red circles, damaged ACA samples by empty circles, and VFCA samples by blue triangles. Labels indicate the animal number.
Metabolites significantly accumulated in the ACA compared to VFCA samples, with corresponding p-values from mixed-effects models, considering both group effect (ACA and VFCA) and time effect. Data analysis was applied to 1H NMR and LC-MS/MS data.
| Cardiac arrest | ||||
|---|---|---|---|---|
| Metabolite | Intercept (p-value) | Time (p-value) | Group (p-value) | R2 |
| Lactate | 23 (<0.001) | 0.33 (0.02) | −12 (<0.001) | 0.98 |
| Succinate | 67 (<0.001) | 3 (0.09) | −72 (<0.001) | 0.99 |
| Malate | 32 (<0.001) | 0.45 (0.46) | −22 (<0.001) | 0.96 |
| Fumarate | 0.002 (0.04) | 0.00007 (0.70) | −0.002 (0.03) | 0.40 |
| Glutamate | 173 (<0.001) | −0.79 (0.79) | −47 (0.01) | 0.97 |
| Hypoxanthine | 15000 (<0.001) | 790 (0.004) | −9700 (<0.001) | 0.94 |
| Uridine | −0.02 (<0.001) | 0.00001 (0.97) | −0.0008 (0.004) | 0.75 |
| Cytidine | 0.003 (0.30) | −0.001 (0.10) | −0.008 (0.008) | 0.23 |
Figure 4The effect of asphyxia on the plasma metabolome of ACA animals. (a) Chart for the BSPC model obtained for no-damaged ACA animals during the asphyxial period. The dashed lines correspond to the limit of 2 standard deviations. The trajectories of the no-damaged animals are represented with red lines, while the trajectories of the damaged animals with grey lines. (b) PCA score scatter plot of plasma samples belonging to ACA animals at baseline and at the last minute of the asphyxial period. The explained variance of the first two components is 80%. Baseline samples are represented by green circles, no-damaged ACA samples by red circles, and damaged ACA samples by empty circles. (c) Modifications of succinate concentration over the asphyxial period for each ACA animal reported in the x-axis. Numerical labels correspond to the asphyxial minute. No-damaged ACA samples are represented by red circles, and damaged ACA samples by empty circles.
Metabolites significantly modified during the asphyxial period identified by mixed-effects models (linear model with interaction), considering both group effect (ACA damaged and no- damaged) and time effect, with corresponding p-values. Data analysis was applied to 1H NMR and LC-MS/MS data.
| Asphyxial period | |||||||
|---|---|---|---|---|---|---|---|
| Metabolite | Significant variation in time | Intercept (p-value) | Time (p-value) | Group (p-value) | Time*group (p-value) | R2 | |
| damaged ACA | no-damaged ACA | ||||||
| Argininosuccinate | ↑ | — | 0.22 (0.003) | −0.0002 (0.9) | −0.03 (0.7) | 0.013 (0.003) | 0.82 |
| Succinate | ↑ | — | 4.1 (0.5) | 0.3 (0.8) | −16 (0.04) | 8 (<0.001) | 0.77 |
| Ornithine | ↑ | — | 61 (<0.001) | 0.2 (0.3) | −0.7 (0.9) | 0.5 (0.046) | 0.98 |
| Glycine | ↑ | — | 522 (<0.001) | 1 (0.3) | −26 (0.8) | 4 (0.03) | 0.97 |
| Glutamate | ↑ | ↓ | 170 (<0.001) | −2 (0.06) | −38 (0.1) | 10 (<0.001) | 0.79 |
| Aspartate | ↑ | — | 36 (0.01) | −0.3 (0.3) | −10 (0.5) | 0.9 (0.04) | 0.95 |
| Tyrosine | ↑ | — | 38 (<0.001) | 0.1 (0.4) | 8 (0.2) | 0.7 (0.03) | 0.87 |
| Phenylalanine | ↑ | — | 44 (<0.001) | 0.4 (0.07) | 9 (0.1) | 0.8 (0.009) | 0.91 |
| Leucine + Isoleucine | ↑ | — | 204 (<0.001) | 0.6 (0.3) | 24 (0.5) | 1.8 (0.04) | 0.95 |
| Acetylcarnitine | ↑ | — | 2.4 (<0.001) | −0.03 (0.2) | −0.3 (0.5) | 0.14 (0.006) | 0.84 |
| Free carnitine | ↑ | — | 5 (<0.001) | 0.005 (0.8) | −0.62 (0.4) | 0.08 (0.01) | 0.90 |
| Hypoxanthine | ↑ | — | 4612 (0.003) | 279 (0.2) | −1839 (0.3) | 1211 (0.004) | 0.82 |
| α-Ketoglutarate | ↑ | ↓ | 19 (<0.001) | −0.5 (0.05) | −6 (0.3) | 1.1 (0.009) | 0.87 |
| Malate | ↑ | — | 13 (0.001) | 0.4 (0.2) | −4.4 (0.2) | 2.7 (<0.001) | 0.90 |
| Lactate | ↑ | — | 19 (0.002) | 0.79 (0.008) | −9 (0.02) | — | 0.95 |
↑↓ indicate if the metabolite increased or decreased in time, respectively.
Figure 5The effect of CPR on the plasma metabolome of VFCA animals. Score scatter plot of the ptPLS2-DA model of VFCA plasma samples at the beginning (turquoise triangles) and at the end (blue triangles) of CPR.
Metabolites significantly accumulated during CPR in VFCA samples, with corresponding p-values and q-values for the Wilcoxon test applied to 1H NMR and LC-MS/MS data, and with mean, minimum and maximum fold change increase.
| CPR in VFCA | ||||
|---|---|---|---|---|
| Metabolite | p-value | q-value | Mean Fold Change | Min-Max Fold Change |
| Lactate | 0.04 | 0.12 | 0.53 | 0.01–1.52 |
| Succinate | 0.002 | 0.01 | 5.39 | 0.25–10.35 |
| Malate | 0.006 | 0.03 | 2.11 | 0.01–3.40 |
| α-ketoglutarate | 0.006 | 0.03 | 0.86 | 0.21–2.53 |
| Hypoxanthine | 0.002 | 0.01 | 1.92 | 0.09–6.02 |
| Glutamate | 0.004 | 0.02 | 0.55 | 0.09–1.15 |
| Argininosuccinate | 0.002 | 0.01 | 1.51 | 0.31–7.97 |
| Ornithine | 0.06 | 0.15 | 0.08 | 0.01–0.20 |
| Aspartate | 0.03 | 0.08 | 0.57 | 0.01–2.71 |
| Choline | 0.002 | 0.01 | 1.14 | 0.19–2.83 |
| Alanine | 0.01 | 0.05 | 0.32 | 0.15–0.71 |
| Free carnitine | 0.002 | 0.01 | 0.32 | 0.07–1.01 |
| Acetylcarnitine | 0.01 | 0.05 | 0.61 | 0.01–1.28 |
| Methionine | 0.01 | 0.05 | 0.15 | 0.01–0.31 |
| Phenylalanine | 0.01 | 0.05 | 0.27 | 0.05–0.50 |
| Tyrosine | 0.004 | 0.02 | 0.31 | 0.07–0.69 |
| Glycine | 0.01 | 0.05 | 0.18 | 0.01–0.40 |
| Inosine | 0.03 | 0.08 | 1.33 | 0.01–3.71 |
| Uridine | 0.02 | 0.08 | 2.22 | 0.01–5.07 |
| Cytidine | 0.03 | 0.08 | 0.52 | 0.01–2.72 |